01875 TOT BIOPHARM-B
- 2.000
- 0.0000.00%
TOT BIOPHARM-B News
Changes in Hong Kong stocks | Dongyao Pharmaceutical rose 4%, and the first quarter revenue surged 68% and turned a loss into a profit
Gelonghui May 14 | Dongyao Pharmaceutical-B (1875.HK) rose 4% to HK$2.08, a record high since this year. Dongyao Pharmaceutical announced its results for the first quarter of 2024. Operating revenue increased 68% year on year to about 223 million yuan, and net profit was about 7.409 million yuan, turning a year-on-year loss into a profit. According to the announcement, revenue growth was mainly due to a sharp increase in sales of self-developed products and continued growth in the CDMO/CMO business.
Dongyao Pharmaceutical-B (01875) achieved net profit of about 7.409 million yuan in the first quarter, turning a year-on-year loss into profit
Dongyao Pharmaceutical-B (01875) announced its results for the first quarter of 2024. Operating revenue increased 68% year on year to about 223 million yuan, and net profit was about 7.409 million yuan, turning a year-on-year loss into a profit.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Baili Tianheng and Shenzhou Cell turned losses into profits! Many biomedical companies on the Science and Technology Innovation Board ushered in a “good start” in Q1
In the first quarter of 2024, many parts of the country successively issued relevant policies to support the high-quality development of the biomedical industry or innovative pharmaceutical devices to continuously optimize the biomedical innovation environment.
東曜藥業-B：2023年年報
Dongyao Pharmaceutical-B (1875.HK): Park Hin-ting is growing rapidly, and the ADC CDMO business has obvious advantages
Commentary opinion: The commercialization of listed products has been promoted smoothly, and performance has grown rapidly: the company's revenue in 2023 was 781 million yuan, an increase of 77% over the previous year, and the net loss was drastically reduced to 37.76 million yuan, a decrease of 25% over the previous year.
Featured announcements | Fuyao Glass's net profit in 2023 increased 18.37% year on year; passenger occupancy rates of the three major airlines all recovered to more than 80% in February
Meitu's adjusted net profit in 2023 was about 370 million yuan, up 233.2% year on year; Longhu Group's total contract sales amount for February was 5.75 billion yuan.
Dongyao Pharmaceutical-B (01875.HK) announced annual results, a sharp increase in revenue of 77%, and the group's hematopoietic capacity continued to increase
Gelonghui March 15 | Dongyao Pharmaceutical-B (01875.HK) announced that in 2023, the Group's revenue was RMB 780,629 thousand, an increase of 77% over the previous year. Among them, product sales revenue was RMB 630,207 thousand, an increase of 107% over the previous year. The main contribution was due to a significant increase in sales performance of the core product Park Xinting (bevacizumab injection). CDMO/CMO business revenue was RMB 140,898 thousand, up 94% year over year. Due to no one-time authorization income for the full year of 2023 (RMB 54,151 thousand for the full year of 2022)
TOT BIOPHARM-B: ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 2023
A major favorable raid, and the 1.6 trillion innovative drug sector is booming!
The advantage suddenly “smashed” into the pharmaceutical sector!
Hong Kong biotech stocks strengthened collectively, and Connoya surged more than 11%
Gelonghui, March 11 | The biotechnology sector of the Hong Kong stock market rose collectively. Among them, Dongyao Pharmaceutical-B rose more than 16%, Connoa-B rose by more than 11%, Beihai Kangcheng-B rose 10%, Kingsley Biotech rose more than 5%, and Cordi-B, Fangda Holdings, Rongchang Biotech, and Cornerstone Pharmaceutical-B rose more than 4%.
Dongyao Pharmaceutical-B (01875.HK) plans to hold a board meeting on March 15 to approve annual results
Gelonghui March 5 | Dongyao Pharmaceutical-B (01875.HK) announced that the company will hold a board meeting on March 15, 2024 (Friday) to consider and approve the Group's annual results for the year ended December 31, 2023, and to deal with other matters.
TOT BIOPHARM-B: DATE OF BOARD MEETING
A quick overview of the Hong Kong market | The Hang Seng Index rose nearly 2%, and the Science Index rose nearly 3%; insurance, real estate and other sectors were strong throughout the day
Technet stocks were strong. Meituan rose nearly 5%, Bilibili and Kuaishou rose more than 3%, Xiaomi and Jingdong rose more than 2%, Baidu, Ali, and Tencent rose more than 1%, and NetEase followed; insurance stocks were strong throughout the day. China Ping An rose more than 6%, China Life Insurance rose nearly 5%, and AIA Insurance rose more than 2%.
Intraday Overview | The three major indices rose slightly, and the Tech Index rose nearly 2%; auto stocks and biotech stocks rose strongly. NIO rose nearly 8%, and Pharmaceutical Biotech rose more than 9%
Most Technology Network stocks rose, with Station B up more than 4%; Meituan and NetEase up more than 3%; mobile phone equipment stocks showed active performance, with Shunyu Optical Technology up more than 7% and Gaowei Electronics by more than 5%; pharmaceutical distribution stocks improved, Ali Health rose more than 8%, and JD Health rose nearly 5%.
Intraday Overview | The Tech Index fell more than 2%, Apple concept stocks and pharmaceutical stocks had the highest declines, and Shunyu Optical Technology fell more than 8%
Technet stocks collectively weakened, with Xiaomi falling nearly 4%, Meituan falling nearly 3%, and Kuaishou falling more than 2%; domestic housing stocks continued to decline, with Country Garden falling more than 3%; Longhu Group, Xincheng Development, and Sunac China falling nearly 2%; auto stocks were weak, with Zero Sports Auto and NIO falling more than 5%, and Xiaopeng Motors falling more than 4%.
Changes in Hong Kong stocks | Dongyao Pharmaceutical-B (01875) is now up more than 8%, and overseas authorized transactions for domestic ADCs are hot
Dongyao Pharmaceutical-B (01875) is currently up more than 8%. As of press release, it is up 8.12% to HK$2.13.
Changes in Hong Kong stocks | Dongyao Pharmaceutical-B (01875) boosted by more than 23%, ADC innovation and development acceleration agencies previously recommended focusing on ADC CDMO innovative pharmaceutical companies, etc.
Dongyao Pharmaceutical-B (01875) rose more than 23%. As of press release, it was up 21.91% to HK$2.17, with a turnover of HK$2,496 million.
Innovative drugs, the standard-bearer of the Hong Kong stock market
However, the protagonist leading the rebound of A/H shares in this round is innovative pharmaceuticals+consumer electronics. Judging from the past half month, consumer electronics has performed better in A-shares, while innovative drugs have performed more fiercely in Hong Kong stocks.
TOT Biopharm's Loss Narrows in January-September Period
TOT Biopharm International's (HKG:1875) loss attributable to shareholders narrowed to 32.4 million yuan for the period between January and September from 40.5 million yuan a year earlier. The biopharm
Analysis
Price Target
No Data
